Skip to main content

Biocon Biologics Global

Biocon Biologics Global plc operates as the UK-incorporated biosimilars subsidiary of Indian biopharmaceutical enterprise Biocon Ltd. The company researches, manufactures, and commercializes biosimilar insulins, monoclonal antibodies, and recombinant proteins, including biosimilar glargine, trastuzumab, and adalimumab. Main revenue drivers comprise global commercial sales of biosimilar insulins and oncology therapeutics alongside partnership licensing royalties. Biocon Biologics serves hospital networks, endocrinologists, oncologists, prescription pharmacies, and chronic disease patients across North America, Europe, and emerging markets. The company holds a world-leading market position as an integrated pure-play biosimilars enterprise delivering affordable biologic medicines. Headquartered in London, UK, with operational headquarters in Bengaluru, India, it operates as a core subsidiary of Biocon Ltd.

2 of the funds FundTelligence covers report a position in Biocon Biologics Global.

Legal name
Biocon Biologics Global PLC
Sector
Health Care
Country
United Kingdom
Funds holding it
2

Funds holding Biocon Biologics Global

Loading...